Clinical Trial Update: RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RC48 as neoadjuvant chemotherapy in HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48 (disitamab vedotin)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN